Targeting specific proteins to treat rare appendix cancers
CDK4/6 inhibition: a novel therapeutic strategy for GNAS-mutant gastrointestinal malignancies
['FUNDING_R21'] · UNIVERSITY OF CALIFORNIA, SAN DIEGO · NIH-10675743
This study is looking at a new way to treat a type of appendix tumor that can become aggressive, by using a special treatment that targets certain proteins, and it aims to help patients with these tough cancers feel better and have better outcomes.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN DIEGO (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-10675743 on ClinicalTrials.gov |
What this research studies
This research investigates a new treatment approach for mucinous neoplasms of the appendix, which can progress to aggressive cancer. The study focuses on inhibiting cyclin-dependent kinases (CDK) 4 and 6, which may be particularly effective against these tumors. By understanding the genetic mutations involved, particularly in the GNAS oncogene, the research aims to develop targeted therapies that could improve outcomes for patients with these challenging malignancies. Patients may be treated with this novel approach to potentially enhance the effectiveness of their cancer care.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with mucinous neoplasms of the appendix or related gastrointestinal malignancies, particularly those with inoperable disease.
Not a fit: Patients with benign appendiceal conditions or those with other types of cancers not related to GNAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with aggressive appendix cancers, improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results in targeting CDK4/6 in other cancer types, suggesting potential for success in this novel application.
Where this research is happening
LA JOLLA, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN DIEGO — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LOWY, ANDREW M — UNIVERSITY OF CALIFORNIA, SAN DIEGO
- Study coordinator: LOWY, ANDREW M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.